About: Vildagliptin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vildagliptin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions. (en)
http://linked.open...generalReferences	# Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17244786 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	The elimination half-life is approximately 90 minutes. (en)
http://linked.open...ugbank/indication	Used to reduce hyperglycemia in type 2 diabetes mellitus. (en)
sameAs	Vildagliptin Vildagliptin
Title	Vildagliptin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/bindingdb/11695 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/chemspider/5293734 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/drugbank/DB04876 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/pubchem-compound/6918537 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/pubchem-substance/99443227 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/pharmgkb/PA165958346 http://linked.opendata.cz/resource/drugbank/drug/DB04876/identifier/wikipedia/Vildagliptin
http://linked.open...mechanismOfAction	Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1. (en)
http://linked.open.../drugbank/synonym	Vildagliptin (en) Galvus (en) EQUA (en) Jalra (en) LAF 237 (en) LAF237 (en) NVP-LAF-237 (en) NVP-LAF237 (en) Xiliarx (en) LAF-237 (en)
http://linked.open...nk/proteinBinding	9.3% (en)
http://linked.open...ynthesisReference	Stephen Winter, Jordi Bosch, Jordi Puig Serrano, Jose Javier Soto, "PROCESS FOR PREPARING VILDAGLIPTIN." U.S. Patent US20080167479, issued July 10, 2008. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0486919
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5C0D-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5C13-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5C12-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5C0F-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5C10-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5C11-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5C0B-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5C09-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5C0C-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5C0A-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Vildagliptin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5C19-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5C1A-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5C14-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5C15-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5C17-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5C16-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5C18-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	274901-16-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5C1F-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5C21-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5C22-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5C1E-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5C1D-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5C20-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5C0E-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5C1B-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5C1C-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software